Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05783570 | To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | unknown | Phase 1 | 12 | EutilexINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05475210 | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | unknown | Phase 1 | 9 | Molecular Targeting Technologies, Inc.INDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05798026 |
| A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy |
| unknown |
| Phase 1 |
| 15 |
| EutilexINDUSTRY |
| 1 |
| Mar 13, 2024 |
| clinicaltrials |
| NCT06139536 | Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients | unknown | Phase 1 | 210 | Bio-Thera SolutionsINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03975907 | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | unknown | Phase 1 / Phase 2 | 121 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05103046 | First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 68 | 1200 Pharma, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05894421 | TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers | unknown | Phase 1 | 92 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06304597 | Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy(PREDICT) | unknown | Phase 1 | 18 | University Medical Center GroningenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06300489 | Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | unknown | Phase 1 | 30 | Zhejiang Cancer HospitalOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05111860 | Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy | unknown | Phase 1 / Phase 2 | 20 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04605185 | Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04766320 | Study on TIL for the Treatment of r/r Gynecologic Tumors | unknown | Phase 1 | 15 | Shanghai 10th People's HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05370547 | Chidamide Bridging for CAR-T Therapy | unknown | Phase 1 / Phase 2 | 120 | Chinese PLA General HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05877664 | Study of ZG0895.HCl in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06225921 | Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas | unknown | Phase 1 | 6 | West China HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06237413 | A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 110 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06242249 | Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06205082 | A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor | unknown | Phase 1 | 81 | LittDD Medicines LtdINDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05033925 | Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 324 | Gadjah Mada UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06279767 | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | unknown | Phase 1 / Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281860 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration(PITHAC) | unknown | Phase 1 | 39 | Dr Jean Yannis PERENTESOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03576378 | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | unknown | Phase 1 / Phase 2 | 41 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05574881 | Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 72 | Fudan UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05346198 | Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma | unknown | Phase 1 | 15 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05868083 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma | unknown | Phase 1 | 16 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06206902 | F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma | unknown | Phase 1 | 55 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05971862 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Oscotec Inc.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06013111 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors | unknown | Phase 1 | 9 | China Medical University, ChinaOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT01754402 | Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Cristina GasparettoOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03375983 | Plasmodium Immunotherapy for Advanced Cancers | unknown | Phase 1 / Phase 2 | 20 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03474822 | Plasmodium Immunotherapy for Breast and Liver Cancers | unknown | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04934514 | Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 97 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06266871 | SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 64 | West China HospitalOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255262 | Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 30 | China Medical University, ChinaOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05028933 | IMC001 for Clinical Research on Advanced Digestive System Malignancies | unknown | Phase 1 | 48 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05213195 | NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | unknown | Phase 1 | 38 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT03274479 | PBF-1129 in Patients With NSCLC | unknown | Phase 1 | 18 | Palobiofarma SLINDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04984668 | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | unknown | Phase 1 / Phase 2 | 216 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05842317 | Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06074029 | Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05358379 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Feb 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 15, 2024source: clinicaltrials